Leadership Overview
Bristol-Myers Squibb has 10 executives leading key functions including oncology commercialization, financial operations, and technology strategy.
Driven by a commitment to scientific innovation, Bristol-Myers Squibb is dedicated to discovering, developing, and delivering transformative medicines that address serious unmet patient needs across critical therapeutic areas, aiming to improve and extend lives globally.
Driven by a commitment to scientific innovation, Bristol-Myers Squibb is dedicated to discovering, developing, and delivering transformative medicines that address serious unmet patient needs across critical therapeutic areas, aiming to improve and extend lives globally.
Leadership Roles at Bristol-Myers Squibb
David Elkins - Executive Vice President and Chief Financial Officer
David Elkins, the Executive Vice President and Chief Financial Officer at Bristol-Myers Squibb, directs the company's comprehensive financial strategy and operations. Elkins oversees all aspects of financial planning, capital allocation, investor relations, and corporate accounting, ensuring fiscal discipline and driving sustainable growth. This executive's leadership is critical in managing the financial resources necessary for Bristol-Myers Squibb's extensive research and development pipeline, particularly in oncology, cardiovascular disease, immunoscience, and virology. By optimizing financial performance, David Elkins supports the organization's ability to invest in groundbreaking therapies and expand its global reach. The financial stewardship provided by Elkins ensures the company maintains a strong market position and can continue its mission of discovering, developing, and delivering innovative medicines to patients worldwide. Elkins's strategic financial management underpins the company's long-term viability and its capacity to address significant unmet medical needs.
Brandon Taverni - Vice President, BD and Strategic Finance, Chief Financial Officer Support Lead
Brandon Taverni, the Vice President, BD and Strategic Finance, Chief Financial Officer Support Lead at Bristol-Myers Squibb, provides critical financial leadership and support for business development initiatives. Taverni's responsibilities include evaluating strategic financial opportunities, managing complex financial modeling, and supporting the Chief Financial Officer in key decision-making processes. This executive plays a vital role in assessing potential mergers, acquisitions, and strategic partnerships that align with Bristol-Myers Squibb's long-term growth objectives and therapeutic focus areas. Brandon Taverni's expertise in strategic finance ensures that the company can effectively allocate capital towards advancing its pipeline of innovative medicines for oncology, cardiovascular disease, and other critical conditions. Taverni's financial acumen is instrumental in driving the company's mission to discover, develop, and deliver transformative treatments. The financial strategies developed under Taverni's guidance support Bristol-Myers Squibb's commitment to addressing significant unmet medical needs globally.
Andreia Pierce - Head Ed, Oncology Commercialization S & O To Chief of Staff & Senior VP
Andreia Pierce, the Head Ed, Oncology Commercialization S & O To Chief of Staff & Senior VP at Bristol-Myers Squibb, directs strategic initiatives within the oncology commercialization sector. This leadership role involves aligning operational strategies with the Chief of Staff and Senior VP's directives to enhance market penetration for critical cancer therapies. Pierce's responsibilities encompass optimizing commercialization processes, ensuring seamless integration of sales and operations, and driving efficiency across the oncology portfolio. The focus remains on translating scientific advancements into accessible treatments for patients battling cancer. This executive contributes to the company's mission by ensuring that innovative oncology medications reach the patients who need them most, supporting Bristol-Myers Squibb's commitment to tackling serious diseases. Pierce's oversight ensures that commercialization efforts directly support the company's overarching goal of improving patient outcomes through groundbreaking therapies.
Umang Srivastava - Strategy Director, Transformation & Gps Chief of Staff
Umang Srivastava, the Strategy Director, Transformation & Gps Chief of Staff at Bristol-Myers Squibb, spearheads critical transformation initiatives and provides strategic support to the Chief of Staff within Global Product Strategy. Srivastava's role involves architecting and executing strategic plans that drive operational efficiency and foster innovation across the organization. This executive focuses on enhancing the effectiveness of Global Product Strategy through targeted transformation projects, ensuring alignment with the company's overarching mission to address serious patient needs. Umang Srivastava's contributions are vital in navigating complex market dynamics and optimizing the development and commercialization pathways for Bristol-Myers Squibb's therapeutic portfolio. By driving strategic change and ensuring seamless operational integration, Srivastava supports the company's commitment to delivering life-changing medicines. The strategic direction provided by Srivastava is integral to Bristol-Myers Squibb's pursuit of scientific breakthroughs and its dedication to improving global health outcomes.
Nicholas Alexiades - Senior Director, Information Technology & Business Partner & Chief Technology Officer, Summit (West)
Nicholas Alexiades, the Senior Director, Information Technology & Business Partner & Chief Technology Officer, Summit (West) at Bristol-Myers Squibb, leads critical information technology functions and business partnerships. Alexiades is responsible for driving technological innovation and ensuring robust IT infrastructure to support the company's biopharmaceutical operations. This executive's purview includes overseeing technology solutions that enhance research and development, streamline manufacturing processes, and improve patient access to medications. Nicholas Alexiades plays a key role in aligning IT strategy with business objectives, particularly within the Summit (West) region, ensuring that technology investments directly contribute to Bristol-Myers Squibb's mission of addressing serious patient needs. The technological advancements championed by Alexiades are essential for the company's continued success in oncology, cardiovascular disease, immunoscience, and virology. Alexiades's leadership ensures that the company leverages cutting-edge technology to accelerate the delivery of transformative medicines.
John Esposito - Director, Office of Chief of Staff
John Esposito, the Director, Office of Chief of Staff at Bristol-Myers Squibb, manages critical operations and strategic initiatives supporting the Chief of Staff. Esposito's role involves coordinating cross-functional projects, ensuring efficient communication flow, and driving the execution of key organizational priorities. This executive's focus is on enhancing the effectiveness and strategic impact of the Chief of Staff's office, facilitating the seamless operation of Bristol-Myers Squibb's biopharmaceutical endeavors. John Esposito contributes to the company's mission by ensuring that strategic directives are implemented effectively across various therapeutic domains, including oncology and cardiovascular disease. By optimizing internal processes and supporting high-level decision-making, Esposito helps advance the company's commitment to discovering and delivering life-changing medicines. The operational oversight provided by Esposito is crucial for maintaining momentum in the pursuit of addressing serious patient needs worldwide.
Jason Xi - Chief Marketing Officer, Lead
Jason Xi, the Chief Marketing Officer, Lead at Bristol-Myers Squibb, directs the company's global marketing strategies and brand development efforts. Xi is responsible for shaping the market perception and commercial success of Bristol-Myers Squibb's innovative medicines across key therapeutic areas, including oncology, immunology, and virology. This executive leads the development and execution of comprehensive marketing campaigns designed to communicate the value of the company's treatments to healthcare professionals and patients. Jason Xi's strategic vision ensures that the company's scientific advancements are effectively translated into market leadership, driving patient access to critical therapies. By understanding market dynamics and patient needs, Xi guides the organization's efforts to address significant unmet medical challenges. The marketing leadership provided by Xi is integral to Bristol-Myers Squibb's mission of improving global health outcomes through groundbreaking pharmaceutical solutions.
Scott Trautwein - Manager, Chief Technology Officer MSAT Process Validation
Scott Trautwein, the Manager, Chief Technology Officer MSAT Process Validation at Bristol-Myers Squibb, oversees critical process validation activities within the Manufacturing Science and Technology (MSAT) division, supporting the Chief Technology Officer. Trautwein's responsibilities include ensuring that manufacturing processes for Bristol-Myers Squibb's pharmaceutical products meet rigorous quality and regulatory standards. This role is essential for maintaining the integrity and efficacy of medicines developed to treat serious patient needs in areas like oncology and cardiovascular disease. Scott Trautwein's focus on process validation guarantees that the company's production methods are robust, scalable, and compliant with global pharmaceutical regulations. By ensuring the reliability of manufacturing processes, Trautwein directly supports Bristol-Myers Squibb's mission to deliver safe and effective treatments to patients worldwide. The meticulous validation work performed by Trautwein underpins the company's commitment to quality and patient safety.
Hetal Rana - Scientist, Chief Technology Officer Systems and Services Critical Reagents
Hetal Rana, the Scientist, Chief Technology Officer Systems and Services Critical Reagents at Bristol-Myers Squibb, contributes to the advancement of critical reagent systems and services supporting the Chief Technology Officer's initiatives. Rana's scientific expertise is applied to ensure the availability and quality of essential reagents used in research, development, and manufacturing processes. This role is fundamental to maintaining the operational efficiency and scientific integrity of Bristol-Myers Squibb's drug discovery and development programs, particularly in complex therapeutic areas. Hetal Rana's work directly supports the company's ability to innovate and produce vital medications for patients facing serious health conditions. By ensuring the reliability of critical reagents, Rana underpins the company's commitment to scientific excellence and its mission to deliver transformative treatments. The dedication of Rana to maintaining high standards in reagent systems is crucial for Bristol-Myers Squibb's ongoing efforts to address unmet medical needs.
Sharon Tuccillo - Senior Executive Associate To Chief Information Officer
Sharon Tuccillo, the Senior Executive Associate To Chief Information Officer at Bristol-Myers Squibb, provides comprehensive executive support to the Chief Information Officer, facilitating strategic IT operations and initiatives. Tuccillo manages key administrative functions, coordinates critical projects, and ensures seamless communication within the IT department and across the organization. This role is vital in supporting the CIO's leadership in driving technological advancements that enhance Bristol-Myers Squibb's research, development, and commercialization efforts. Sharon Tuccillo's contributions are essential for the efficient execution of IT strategies aimed at addressing serious patient needs through innovative medicines. By optimizing operational workflows and supporting strategic planning, Tuccillo helps advance the company's mission to discover, develop, and deliver life-changing therapies. The dedicated support provided by Tuccillo is integral to maintaining the technological infrastructure that powers Bristol-Myers Squibb's commitment to global health.
Explore Leadership Teams in Manufacturing
Founded in 1885, Boehringer Ingelheim is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products.
Company Leadership EM
RP
YL
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed, and grain processors and processors; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topical and diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segments products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing,...
Company Leadership CD
DK
KB
Tabuk Pharmaceuticals is a generic pharmaceutical company that delivers quality cost-effective prices in the regulated markets of the MENA region. The company provides to the major therapeutic areas of GI and diabetes, cardiovascular, musculoskeletal, respiratory, infection, and the central nervous system pharmaceuticals.
Company Leadership IS
DB
HR
Grupo NC is a leading Brazilian pharmaceutical company with roots dating back to 2014 when it began as a small pharmacy in Santo André. Officially founded in 1964 with its first factory in São Bernardo do Campo, the company has grown to become one of the largest pharmaceutical industries in Brazil. Grupo NC operates with a dual business model serving both B2B and B2C markets, offering innovative healthcare solutions and pharmacy retail services. The company maintains a strong presence in South America, particularly Brazil, while also expanding into Asian markets. Grupo NC is committed to sustainable development, innovation in healthcare solutions, and excellence in all operational aspects. The company's core values emphasize continuous improvement, responsible innovation, and making a positive impact in the markets where they operate.
Company Leadership DM
ND
Frequently Asked Questions Regarding Bristol-Myers Squibb Top Executives and Leadership Team
